- Home
- ZURA vs LPTX Comparison
ZURA vs LPTX Comparison
Compare ZURA & LPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZURA
- LPTX
- Stock Information
- Founded
- ZURA 2022
- LPTX 2011
- Country
- ZURA United States
- LPTX United States
- Employees
- ZURA N/A
- LPTX N/A
- Industry
- ZURA Biotechnology: Biological Products (No Diagnostic Substances)
- LPTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ZURA Health Care
- LPTX Health Care
- Exchange
- ZURA Nasdaq
- LPTX Nasdaq
- Market Cap
- ZURA 101.2M
- LPTX 119.6M
- IPO Year
- ZURA N/A
- LPTX N/A
- Fundamental
- Price
- ZURA $1.22
- LPTX $0.42
- Analyst Decision
- ZURA Buy
- LPTX Buy
- Analyst Count
- ZURA 6
- LPTX 3
- Target Price
- ZURA $15.80
- LPTX $8.50
- AVG Volume (30 Days)
- ZURA 241.3K
- LPTX 441.1K
- Earning Date
- ZURA 05-08-2025
- LPTX 03-17-2025
- Dividend Yield
- ZURA N/A
- LPTX N/A
- EPS Growth
- ZURA N/A
- LPTX N/A
- EPS
- ZURA N/A
- LPTX N/A
- Revenue
- ZURA N/A
- LPTX N/A
- Revenue This Year
- ZURA N/A
- LPTX N/A
- Revenue Next Year
- ZURA N/A
- LPTX N/A
- P/E Ratio
- ZURA N/A
- LPTX N/A
- Revenue Growth
- ZURA N/A
- LPTX N/A
- 52 Week Low
- ZURA $1.10
- LPTX $0.40
- 52 Week High
- ZURA $6.35
- LPTX $4.79
- Technical
- Relative Strength Index (RSI)
- ZURA 37.61
- LPTX 19.54
- Support Level
- ZURA $1.10
- LPTX $0.40
- Resistance Level
- ZURA $1.30
- LPTX $0.46
- Average True Range (ATR)
- ZURA 0.12
- LPTX 0.03
- MACD
- ZURA 0.02
- LPTX 0.07
- Stochastic Oscillator
- ZURA 27.59
- LPTX 20.62
About ZURA Zura Bio Limited
Zura Bio Ltd is a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders.
About LPTX Leap Therapeutics Inc.
Leap Therapeutics Inc is in developing targeted antibody therapies for cancer treatment, focusing on inhibiting tumor-promoting pathways, targeting cancer-specific cell surface molecules, and activating the immune system against cancer cells. The company's lead program, DKN-01, targets Dickkopf-related protein 1 (DKK1) and is in clinical trials for esophagogastric, gynecologic, and colorectal cancers. Their second program, FL-301, targets Claudin18.2-expressing cells. Additionally, the company has two preclinical antibody programs, FL-302 and FL-501, aimed at developing transformative cancer treatments. Operating as a single segment, the company's sole focus is on developing innovative drugs to address unmet needs in cancer therapy. .